Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG. Stewart AK, et al. Among authors: ramakrishnan v. Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8. Blood Cancer J. 2019. PMID: 30718503 Free PMC article. Clinical Trial.
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG. Li D, et al. Among authors: ramakrishnan v. Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18. Mol Cancer Ther. 2013. PMID: 23598530
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD. Patnaik A, et al. Among authors: ramakrishnan v. Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17. Cancer Chemother Pharmacol. 2014. PMID: 24633809 Clinical Trial.
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.
Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodríguez O, Guzman M, Sampath D, Nannini M, Xiao Y, Wagle MC, Wu JQ, Wongchenko M, Hampton G, Ramakrishnan V, Lackner MR, Saura C, Roda D, Cervantes A, Tabernero J, Patel P, Baselga J. Yan Y, et al. Among authors: ramakrishnan v. Clin Cancer Res. 2013 Dec 15;19(24):6976-86. doi: 10.1158/1078-0432.CCR-13-0978. Epub 2013 Oct 18. Clin Cancer Res. 2013. PMID: 24141624
TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors.
Austin RJ, Lemon BD, Aaron WH, Barath M, Culp PA, DuBridge RB, Evnin LB, Jones A, Panchal A, Patnaik P, Ramakrishnan V, Rocha SS, Seto P, Sexton K, Strobel KL, Wall R, Yu S, Yu TZ, Law CL, Baeuerle PA, Wesche H. Austin RJ, et al. Among authors: ramakrishnan v. Mol Cancer Ther. 2021 Jan;20(1):109-120. doi: 10.1158/1535-7163.MCT-20-0061. Epub 2020 Nov 17. Mol Cancer Ther. 2021. PMID: 33203731
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V. Uppal H, et al. Among authors: ramakrishnan v. Clin Cancer Res. 2015 Jan 1;21(1):123-33. doi: 10.1158/1078-0432.CCR-14-2093. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370470
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL. Koeppen H, et al. Among authors: ramakrishnan v. Clin Cancer Res. 2014 Sep 1;20(17):4488-98. doi: 10.1158/1078-0432.CCR-13-1836. Epub 2014 Mar 31. Clin Cancer Res. 2014. PMID: 24687921 Free PMC article. Clinical Trial.
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V. Bhaskar V, et al. Among authors: ramakrishnan v. Cancer Res. 2003 Oct 1;63(19):6387-94. Cancer Res. 2003. PMID: 14559828
1,099 results